Global Biosimilars (Follow-on biologics) Market: An Analysis -- New Report by Koncept Analytics

Dec. 3, 2010 - PRLog -- Biosimilars or FOBs (Follow-on biologics) refer to generic versions of patented branded biological drugs, developed subsequent to the patent expiry of brand name products. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest market segment since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications.

Overburdened due to rising healthcare costs, ageing population, expensive drugs and pharmaceutical expenditure, biosimilar market is getting boost from increasing user acceptance and emerging Indian and Chinese markets. The major challenge for the biosimilar market is risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics are going to be off patent by 2015 and an anticipated approval pathway in U.S will open up potentially largest market. The growth potential of the biosimilars market is expected to be strong, with patents for a number of second-generation therapeutic proteins (Enbrel, Remicade, Herceptin, etc.) slated for expiry between 2013 and 2019. The global biosimilars market is highly fragmented with the presence of some leading players such as Biocon, Dr Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt.

The report broadly includes the following

1. Global Biopharmaceutical Market

2. Global Biosimilars Market

2.1 Overview
2.2 Market Size
2.3 Geographical Segmentation
2.4 Currently Marketed Biosimilars

3. Market Drivers

4. Market Constraints

5. Opportunities

6. Market Outlook

7. Major Players

7.1 Teva Pharmaceuticals Industries Ltd.
7.2 Biocon
7.3 Hospira Inc.

Charts and Figures

Biopharmaceutical Value Chain
Global Biopharmaceutical Market (2004-2009)
Global Biopharmaceutical Market by Product (2009)
Categories of Biosimilars Market
Biosimilars Development Process
Difference between Small Molecule Generics and Biosimilars
Global Biosimilar Market Revenue (2008-2014F)
Global Biosimilars Market by Product (2009)
Global Market Potential for Biosimilars in Different Categories (2009)
Major Blockbuster biologics whose patents will expire from 2012- 2019
Marketed Biosimilars by Product Group
Total Healthcare Expenditure Per Capita in Selected Developed Countries (2008)
Real Annual Growth in per Capita Health Spending (%): 2000-2008
Potential Market Potential for Biosimilars
Leading Players in Biosimilars market and Products in Pipeline
Ageing Population Worldwide (age>65) 2005-2015F
Cost Comparison of Biosimilars and Innovator Biologics
Biosimilar Approval in EU
Indian Biosimilars Market Revenue (2008-2012F)
India’s Biosimilar Market Breakdown (2009)
Potential Global Market for Biosimilars (2008-2015)
Number of Biologics Scheduled to Go-off Patent (2008-2015)
Annual Revenues of Teva Pharmaceuticals (2005-2009)
Annual Revenues of Biocon (FY06-FY10)
Annual Revenues of Hospira Inc. (2009)

For more information, please visit http://www.konceptanalytics.com/reportDetail.aspx?reportI...

To know more about us http://www.konceptanalytics.com

# # #

Koncept Analytics, founded in 2005, works with the clients in developing an understanding of the various industries – segments and sub-segments, companies, competitors and suppliers.